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More intensive and/or frequent hemodialysis may provide
clinical benefits to patients with end-stage renal disease;
however, these dialysis treatments are more convenient
to the patients if provided in their homes. Here we created
a standardized model, based on a systematic review of
available costing literature, to determine the economic
viability of providing hemodialysis in the home that arrays
costs and common approaches for assessing direct medical
and nonmedical costs. Our model was based on data from
Australia, Canada, and the United Kingdom. The first year
start-up costs for all hemodialysis modalities were higher
than in subsequent years with modeled costs for
conventional home hemodialysis lower than in-center
hemodialysis in subsequent years. Modeled costs for
frequent home hemodialysis was higher than both in-center
and conventional home hemodialysis in the United Kingdom,
but lower than in-center hemodialysis and higher than
conventional home hemodialysis in Australia and Canada in
subsequent years. The higher costs of frequent compared
to conventional home hemodialysis were because of higher
consumable usage due to dialysis frequency. Thus, our
findings reinforce the conclusions of previous studies
showing that home-based conventional and more frequent
hemodialysis may provide clinical benefit at reasonable costs.
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There is a growing body of literature demonstrating that
longer and/or more frequent hemodialysis provides substan-
tially improved clinical, biochemical, and health outcomes
benefits for end-stage renal disease patients over conventional
hemodialysis (dialysis performed for 4 h per day, 3 times
per week).1–13 The quality-of-life-related benefits of provid-
ing more intense hemodialysis to patients in their own
home compared with in-center hemodialysis have been
documented.1,5,7
Numerous studies have reported that conventional and
more frequent home hemodialysis are less costly than
conventional in-center hemodialysis.14–25 Existing published
studies describing costs of home hemodialysis have been
written from the payer, patient, and government perspectives.
These economic studies were conducted in a variety
of industrialized nations, with various assumptions, under
an array of funding regimes. This diversity creates difficulty
in generalizing the findings because of the unique character-
istics and funding structures of individual programs. The lack
of consistency within the published literature could help
explain some of the substantial variability in the uptake of
home hemodialysis.
The intent of this paper was to apply lessons from an
analysis of original costing studies comparing in-center
hemodialysis with home hemodialysis in developing a cost
model from the payer’s perspective. Owing to the hetero-
geneity of inputs used within the published analyses, the cost
model is envisioned to provide payers and decision makers
with a comprehensive, robust tool to accurately and
transparently capture the cost of home hemodialysis services.
This costing tool will aid in setting informed, evidence-based
reimbursement policies to expand access to home hemodia-
lysis in general and to more intensive home hemodialysis
specifically.
RESULTS
Our comprehensive base case costing model is presented in
Table 1, separated into perspectives from Australian,
Canadian, and the UK health-care systems. Total costs for
each modality were relatively consistent in year 1. From year
2 onward, conventional home hemodialysis is less expensive
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than in-center hemodialysis. Specifically, the model predicts
that, over time and depending on location, conventional
home dialysis would save payers between $7612 and $12,403
over the first year of conventional in-center hemodialysis.
The model predicts that frequent home hemodialysis, with its
increased costs of consumables and materials, would cost
UK payers $4408 in subsequent years. However, frequent
home hemodialysis would save Canadian payers $3411 and
Australian payers $4036 in subsequent years compared with
first year in-center hemodialysis costs.
In-center hemodialysis costs are stable over time as the
cost to provide hemodialysis in a center is conservatively
assumed to stay relatively constant year after year. Renal
medication, human resources, hospitalizations, consumables,
and facility (overhead) costs are the primary cost drivers for
in-center hemodialysis. Conventional home hemodialysis
and frequent home hemodialysis costs in year 1 are greater
than those in subsequent years, as costs of hemodialysis
reduce in subsequent years after capital investments and
training have been paid for. These conventional home and
frequent hemodialysis costs are driven by renal medication,
capital investment, patient training (primarily training nurse
costs), machines, consumables (more for frequent home
hemodialysis), home preparation, training, and hospitaliza-
tion costs. To illustrate the impact of component costs,
Figure 1 provides a summary of the cost drivers by modality
for Canada.
Sensitivity analysis
The sensitivity analysis demonstrated that changes to the
major drivers of total cost, such as staffing costs and facility
costs, can substantially impact the overall costs. For example,
when evaluating the range of total costs while adjusting the
total allied health-care costs to 25% of the original cost input,
total costs for conventional home hemodialysis in Canada
goes from being less than that for in-center hemodialysis to
more than that in year 1. In comparison, when increasing the
original cost input of total allied health-care costs by 25% in
the United Kingdom in year 1, total costs for in-center
hemodialysis move from being less than to more than
total costs for conventional home hemodialysis. Across all
component costs, there were four instances in year 1 (7.5%)
and one instance in subsequent years (2.4%) where adjusting
the component cost plus or minus 25% changed the total
costs of a hemodialysis modality from being more than to less
than another modality.
DISCUSSION
Derived from data in published cost studies, we have
generated a transparent, logical costing model that includes
both start-up and operating costs for conventional home
hemodialysis and frequent home hemodialysis as compared
with in-center hemodialysis. As anticipated, the results of our
model are consistent with the findings of most costing studies
to date, in that conventional home hemodialysis and frequent
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Figure 1 |Component costs as a percentage of total costs, Canada. CHHD, conventional home hemodialysis; FHHD, frequent home
hemodialysis; ICHD, in-center hemodialysis.
Kidney International (2012) 81, 307–313 309
P Komenda et al.: An economic assessment model for CHHD, FHHD, and ICHD o r ig ina l a r t i c l e
home hemodialysis are similar in cost to in-center hemodial-
ysis in the first year (driven primarily by training costs) but
can be less costly than in-center hemodialysis from the
second year onward, depending on the frequency of dialysis.
The results of the model show that year 1 costs are largely
a result of higher start-up costs, but lower human resource
costs, for home hemodialysis submodalities as compared
with in-center hemodialysis. In year 2 and beyond, conven-
tional home hemodialysis is less expensive than in-center
hemodialysis. Specifically, the model predicts that, over time
and depending on location, conventional home dialysis
would save payers between $7612 and $12,403 over the first
year of conventional in-center hemodialysis. The model
shows that frequent home hemodialysis, with its increased
costs of consumables and materials, would cost UK payers
$4,408 in subsequent years. However, frequent home
hemodialysis would save Canadian payers $3411 and
Australian payers $4036 in subsequent years compared with
the first year in-center hemodialysis costs. Decreased staffing
costs coupled with lower facility overhead and medication
costs drove this cost differential. That is, there are initial
training costs for home hemodialysis patients (and their
family members). Once trained, there are minimal human
resource costs associated with home hemodialysis modalities,
whereas the human resource costs for in-center hemodialysis
stay consistent over time as payers are responsible for the
salaries of staff who provide dialysis.
A review of the published cost studies reveals that all three
forms of home hemodialysis (conventional, nocturnal, and
short daily home hemodialysis) may have economic advan-
tages over in-center hemodialysis.5,7,14–19 These studies also
demonstrate the clinical advantages of more frequent
intensive hemodialysis relative to less frequent hemodialysis
while being cost neutral or cost saving to the payer.1–14
The most persuasive evidence (based upon study size,
quality of study, and number of studies with consistent
results) finds that costs for home hemodialysis are substan-
tially lower than costs for in-center hemodialysis.1,5,7,19,26,27
In addition, costs per quality-adjusted life year appear to be
better for conventional home hemodialysis compared with
in-center hemodialysis.28–30
These studies take numerous perspectives and include
many different costing inputs. No study to date (to our
knowledge) has attempted to summarize the findings of these
studies to come to a comprehensive summary of the
component cost inputs of conventional home hemodialysis
or frequent home hemodialysis when compared with in-
center hemodialysis.
Rates of home hemodialysis utilization vary greatly across
the world. The number of patients on home hemodialysis has
grown significantly over the past several years globally.31
There is considerable variation in reimbursement of hemo-
dialysis expenses around the world. Canada and the United
Kingdom have developed similar, although nonidentical,
methods for reimbursing dialysis services. Canada’s single-
payer universal health-care system funds providers, hospitals,
or provincial programs to provide all dialysis care. Care is
often provided within a case rate payment: CDN $55,466 (US
$45,094) per patient with end-stage renal disease.15 The UK’s
National Health Service funds dialysis care through a special
commission on a countrywide basis through the use of
health-related group payments for care. The health-related
group for hemodialysis, LC01A, had an average payment per
dialysis session of d153 for in-center hemodialysis and d83
for home hemodialysis in 2007, which translates to a yearly
payment of d23,443 (US$37,393) and d18,270 (US$29,142)
per year, respectively.32 The six Australian states are funded to
provide dialysis through a mix of capitation and case
payments.33 One state (Victoria) has added incentives of
AUD$10,000/patient/year paid to renal services for each
nocturnal home hemodialysis patient who is home installed,
with out-of-pocket expenses for water, power, and cleaning
reimbursed at AUD$1,200/year for each home hemodialysis
patient.30
Given these varying payment systems for hemodialysis,
payers may have difficulty synthesizing the published
literature to determine what information is relevant to their
context. Our costing model was developed to assist payers in
understanding the component cost drivers of home versus in-
center hemodialysis in more detail. Decision makers
representing different localities or with costs not consistent
with modeled data should adjust component costs accord-
ingly if attempting to use the model to estimate costs in a
specific local setting. This information can be used to inform
coverage policy development, especially in reference to
developing payment systems that encourage home hemodial-
ysis options (conventional, nocturnal, and short daily home
hemodialysis).
Our costing model has several limitations. As mentioned
previously, our review of the existing costing literature
yielded inconsistent evidence related to costs of conventional
home, frequent home, and in-center hemodialysis between
and within Australia, Canada, and the United Kingdom.
Despite this, we feel that our model is transparent enough to
allow for specific costs to be varied easily by decision makers
in tailoring our analysis to almost any payer model. Because
no one study captured all required cost inputs, the model
used inputs from a variety of studies. As a result,
heterogeneity exists within the methods used by the
referenced cost studies. Our use of sensitivity analysis
attempts to address this.
Costing data for home hemodialysis should be augmented
by randomized control trial data. The National Institutes of
Health (NIH)-sponsored Frequent Hemodialysis Network
trial has recently published results on the clinical outcomes
associated with more frequent in-center hemodialysis,
although currently published data do not yet include a cost
analysis.34,35 In addition, cost-effectiveness analysis could be
used to capture the clinical and cost advantages of home
hemodialysis modalities (conventional, nocturnal, and short
daily home hemodialysis) compared with in-center hemo-
dialysis. Additional research and modeling in this area would
310 Kidney International (2012) 81, 307–313
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help to systematically evaluate both clinical and cost variables
in a variety of settings.
The costing model presented here uses a hybrid of existing
costing data and modeled inputs for key cost drivers across
three hemodialysis modalities in four countries with hetero-
geneous payer models. It can serve as a robust tool for payers
and other decision makers to apply key cost drivers to make
related decisions.
All home hemodialysis modalities have limitations and
may not be the optimal solution for all patients. Improved
access to dialysis delivery systems, with simpler operating
procedures and portability, will allow more patients to
undertake this modality. For those patients likely to receive
kidney transplant within 1 year of dialysis, home hemodial-
ysis likely does not represent an optimal approach, given the
high start-up, home preparation, and training costs. How-
ever, the literature does reveal a large segment of dialysis
patients for whom frequent home hemodialysis, via noctur-
nal home hemodialysis or short daily home hemodialysis,
would be a beneficial approach. In many countries, utiliza-
tion lags behind the evidence base.
Although the costs described within the model inform
reimbursement decision making, they must be contextualized
within the broader clinical literature. Reimbursement policy
should consider these cost and clinical findings. Payers
can take an active role in using reimbursement policy to
encourage clinicians to use the most effective home
hemodialysis approaches. This model provides a tool for
payers to make a cost determination for their patient
population; given the model’s findings of two of the three
locations incurring lower total costs after the first year of
home hemodialysis, this could be an informative exercise
for payers while potentially improving the quality of lives for
patients.
MATERIALS AND METHODS
Three hemodialysis modalities were selected for cost modeling based
on the number and quality of cost studies available. These are as
follows: in-center hemodialysis, conventional home hemodialysis,
and more frequent home hemodialysis. Frequent home hemodialysis
is inclusive of nocturnal home hemodialysis (dialysis performed for
6–10 h per night for up to 7 nights per week) and short daily
home hemodialysis (dialysis performed for 2 to 3 h per day for up to
7 days per week), which is based on the assumption that short daily
home hemodialysis costs are similar to nocturnal home hemodial-
ysis costs, although the authors recognize that small differences in
resource utilization between the two modalities may exist.
Short daily home hemodialysis costs were not specifically included
in the model because of a lack of published, comprehensive
cost data specific to that submodality available at the time of this
analysis.
The current costing studies take different perspectives and were
conducted under a variety of funding regimes. To provide a holistic
view of costs across multiple countries, we constructed a
standardized cost model from the payer/funder perspective using
inputs from published costing studies. The purpose of the model is
to provide payers and decision makers with a comprehensive, robust
tool to accurately and transparently capture the cost of home
hemodialysis services. This costing tool will aid in setting informed,
evidence-based reimbursement policies to expand access to home
hemodialysis in general and to more intensive home hemodialysis
specifically.
The cost model is a transparent spreadsheet that summarizes
component costs for in-center hemodialysis, conventional home
Table 2 | Characteristics of dialysis payment in each country studied based on specific cost variables (online)
Canada41 Australia42 United Kingdom32
Health system Socialized Socialized
Payment mechanism for dialysis Case rate Case rate Case rate with payment
by results program
Direct costs
Patient evaluation/recruitment, training costs Within Within or standard Within
Home preparation NC Min (via patient grant) NC
Machine costs—amortized over 8–10 years or annual rental Standard Within Standard
Pump Standard Within Standard
Consumables and peripheral costs Standard Within Within
Total allied health-care costs (including nursing,
technicians, social workers)
Standard Within Standard
Weigh scales, special chairs, storage carts, over bed
tables, water purification device, wetness detector
Standard Within Standard
Renal medication costs (total) Standard Within Standard
Dialysis monitoring-related laboratory costs Standard Within Standard
Hospitalization costs Out of program Out of program Out of program
Costs of in-center runs Standard Within Standard
Dialysis-related home utility costs NC Standard (from patient block grant) Min
Facility costs Within Within Within
Utility costs (water and electricity) NC Min (via patient grant) Min
Indirect cost variables
Travel costs to and from dialysis NC Standard (from patient block grant) Min
Lost productivity NC NC Min
Abbreviations: Min, payer provides minimal benefit, potential out-of-pocket payment from patient; NC, not covered; Out of program, cost born by payer outside renal
replacement therapy program; Standard, payer covers routine costs; Within, cost not separately reimbursed, but captured within global payment rate.
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hemodialysis, and frequent home hemodialysis within each of
the three countries (Australia, Canada, and the United Kingdom).
The three countries were selected for two reasons: first, over half of
the available published cost data are related to them; and second,
they represent distinct reimbursement systems that are informative
to other similar country reimbursement systems. The United States
was excluded from this analysis because of the unique funding
system associated with Medicare’s end-stage renal disease program
and the limited US cost data specific to the different hemodialysis
modalities.
The model was constructed from a payer’s perspective and
therefore includes component costs that are routinely reimbursed
by payers (summarized in Table 2). Direct medical and well-
documented direct nonmedical costs associated with dialysis
(e.g., transportation to and from dialysis facilities) have been
included. Indirect nonmedical costs (e.g., lost time from work and
unpaid assistance from family members) are not included. Costs are
considered in terms of start-up costs that would only be experienced
in the first year of use, and then ongoing maintenance costs
experienced in year 2 and beyond. As such, variables are segmented
by one-time costs directly related to hemodialysis (e.g., dialysis
training costs) and medical costs (e.g., consumable material costs,
medications, professional reimbursement, and costs of emergency
in-center hemodialysis runs) experienced in the first year of dialysis.
Once these items were established, we added further line items that
would be considered ‘standard’ in a comprehensively reimbursed
home hemodialysis program (e.g., wetness detectors, scales, nursing,
and allied health costs for clinic visits).
The model also provides a sum of all component costs per
hemodialysis modality for year 1 and for subsequent years to derive
a realistic cost picture that differentially accounts for start-up costs
from ongoing costs experienced in subsequent years. It is recognized
that the majority of start-up costs would be experienced in the first
several months of a patient’s dialysis care, but for the purposes
of this model annual costs were used.
Published costing studies and government-sponsored report data
were used to derive annual best cost estimates for each component
cost on a dialysis modality-specific basis. Where available, country-
specific data were utilized. When country-specific data were not
available, we used published data from the Canadian setting. These
data were collected from the Manitoba Renal Program at Seven Oaks
General Hospital in Winnipeg, Canada, where one of the authors
practices.36 Where data conflict existed (e.g., varying prices of
dialysis machines), data inputs were selected from published studies
prioritized by study, country perspective, and quality of the study.
(Modifications were made based on the literature to reflect
differences between the Canadian, Australian, and UK programs
in which extrapolations were used.) Published hospitalization
cost data were not differentiated by year of dialysis in the
literature. We conservatively used an estimate for ‘year 1’ costs for
both ‘year 1’ costs and ‘subsequent years’ costs to keep a proxy for
hospitalization costs in the model without influencing any one
modality’s results.
For each cost variable, costs were inflated to 2010 dollars using
country-specific consumer price index and wage index from the year
in the articles. To standardize costs across countries when country-
specific data were not available, costs were then converted to US
dollars using appropriate currency exchange rates.37–40 (Although
the use of purchasing power parity was considered, the authors
ultimately chose this methodology as the costs are not intended to
be compared across countries and the literature suggests that the
CPI-based approach is an appropriate methodology for this type
of analysis.)
Sensitivity analyses were conducted on all variables using a
standard range of plus or minus 25%. The standard range was
chosen because the source studies did not universally supply
published sensitivity ranges. Each variable was initially analyzed to
consider its impact on the base case cost analysis. Cost input values
were then each varied plus or minus 25% to measure their impact
on overall costs to determine the percentage of time that, across the
plus or minus 25% range, the total costs of the hemodialysis
modalities changed in relative rank order.
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